ADRB2 and congestive heart failure: Given the problems and limitations hampering clinical efficacy of this drug class for advanced human CHF and other heart diseases [5], cardiac GRK5 stimulation (either directly with a small organic molecule or indirectly via β2AR-selective agonism) may offer a new pharmacotherapeutic avenue to augment the cardiac benefits of Aldo inhibitor drugs.